|
|
|
|
 Dr Greg Tucker-Kellogg,
Chief Technology Officer, and Senior Director Systems Biology Lilly Singapore Centre for Drug Discovery Pte Ltd, Singapore Greg Tucker-Kellogg, Ph.D. is Chief Technology Officer, and Senior Director Systems Biology at Lilly Singapore Centre for Drug Discovery, and Adjunct Associate Professor or Biological Sciences at the National University of Singapore. LSCDD is a research site of Eli Lilly and Company.
Dr. Tucker-Kellogg joined Lilly in November 2004 as Director of Bioinformatics, and moved to Singapore in 2005 to become Chief Scientific Officer of Lilly Systems Biology. In mid 2007, Lilly Systems Biology expanded to become Lilly Singapore Centre for Drug Discovery, after which he was named to his current positions. Prior to joining Eli Lilly, Dr. Tucker-Kellogg was Associate Director of Informatics at Millennium Pharmaceuticals, where was responsible for the informatics for Millenniums internal biomarker discovery and pharmacogenomics programs and personalized medicine partnerships. Earlier, as a Principal Scientist at Wyeth Research in Cambridge, he established the first enterprise-wide bioinformatics and analysis framework for microarray expression profiling.
He earned his Ph.D. in Molecular Biophysics and Biochemistry from Yale University, where he studied under Peter Moore, and a B.S. in chemistry and biological sciences from Carnegie-Mellon University. He was a Jane Coffin Childs Memorial Fund Postdoctoral Fellow at Harvard Medical School in the laboratory of Christopher T. Walsh.
Dr. Tucker-Kellogg has served the scientific and professional community in many capacities, including on the Governing Board of the Singapore-MIT Alliance, co-chair of the AACR-FDA-NCI Cancer Biomarkers Collaborative Bioinformatics Subcommittee, the Science Policy Committee of FASEB, the Public Affairs and Policies Committee of the International Society for Computational Biology (ISCB), and the Singapore National Grid Advisory Council. He is a member of the editorial board of PLoS Computational Biology.Appearing: Conference Day Two: Thursday, 18 March 2010 14.45 Deliver biomarkers to enable patient stratification in oncology and diabetes projects using integrated experimental, genomic and epigenetic studies Dr Greg Tucker-Kellogg, Chief Technology Officer, and Senior Director Systems Biology,
Lilly Singapore Centre for Drug Discovery Pte Ltd, Singapore |
|
|
|
|
|
Session sponsor:
Exhibitors:
|
asia research institution poster presentation
* For first 20 confirmed poster presentations
|
|
|
|
|
|
|
|
|
